Project Grant W81XWH1810742

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $766,877 randomized controlled trial to evaluate the efficacy of therapeutic drug monitoring (TDM) for linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The primary objective is to determine if TDM can prevent premature discontinuation of linezolid, a critical drug for treating RR-TB. The...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $335,559 to the University of North Carolina at Chapel Hill to conduct a pilot randomized controlled trial on the feasibility, acceptability, and preliminary effectiveness of a Focal Mass Drug Administration (FMDA) program for household members of pregnant women to protect against malaria in pregnancy (MIP). The key...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $427,000.00 to the New York Blood Center, Inc. to establish a continuous in vitro culture system for the propagation of the Babesia microti parasite in human red blood cells. The overall goal is to create a robust platform for experimental investigation of the receptor-ligand interactions that facilitate B. microti...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $467,400.00 to The Regents of the University of California, San Francisco (UCSF) to develop precise field-friendly methods for quantifying antimalarial drugs in dried blood spot (DBS) samples. The project aims to employ volumetric absorptive microsampling (VAMS) to collect DBS samples and use ultra-performance liquid...

This Project Grant award of $1,373,790 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to optimize next-generation antimalarial drug candidates known as ELQs. The goal is to develop ELQ-596 and related compounds for once-monthly oral prophylaxis against malaria, which would simplify dosing, improve compliance, and reduce costs compared to current options. The research, conducted by a...

This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a longitudinal cohort study to examine the impact of early childhood malaria prevention interventions on malaria risk in school-age children in Ghana. The study, titled "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)", will evaluate the epidemiological and...

This three-year, $1.977 million Project Grant from the Department of the Army Medical Command will support Cytosorbents Medical Inc.'s demonstration of the safety and efficacy of its field-ready blood group antibody (BGA) adsorber in a porcine universal transfusion model. The Military Medical Research and Development program (CFDA 12.420) aims to transform military and public health care through innovative biomedical research solutions for battlefield medicine. Under this award, Cytosorbents...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,071 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a universal transmission blocking vaccine against malaria. The goal is to create a vaccine targeting conserved mosquito-stage antigens that can prevent infection across multiple Plasmodium species that cause malaria. Key aspects...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $702,204 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the London School of Hygiene and Tropical Medicine (LSHTM) to conduct research on complex malaria in India. The key products and services to be delivered through this 5-year project include: Monitoring the changing epidemiology of malaria in Odisha, India through a 4-year community-based cohort study to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $215,751 to the Regents of the University of California at Riverside to identify and characterize RNA-binding proteins (RBPs) and RNA-dependent proteins (RDPs) in the malaria parasite Plasmodium falciparum. The primary goals are to: 1) Adapt and expand an unbiased proteomic approach to identify RDPs from early and late stage gametocytes (sexual...